Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool November 9, 2005 Brian Gorman	Caremark's Room to Grow Fickle investors may fret about near-term growth, but the pharmacy benefit manager is prepared for the long haul. Investors looking for a long-term holding may want to mark a place in their portfolio for this company.
The Motley Fool February 15, 2006 Stephen D. Simpson	Good Marks for Caremark The pharmacy benefits management company should have even more positive operating leverage left in the tank. Investors, take note.
The Motley Fool February 25, 2009 Brian Orelli	The Best Kind of Generic Growth Pharmacy benefit managers profit from penny-pinchers.
BusinessWeek May 9, 2005 Weintraub & Barrett	BW 50: Can Caremark's Health Hold Up? Caremark Rx Inc. faces a growing set of legal and market challenges, but Its drug-benefit business is soaring, and its CEO remains upbeat about the future.
The Motley Fool February 22, 2005 Brian Gorman	Novartis Embraces Generics The company is taking a different path from its branded pharmaceutical peers. The company's strategy may make its stock worth a closer look.
The Motley Fool April 29, 2010 Brian Orelli	A Prescription to Investigate Further Let's not worry just yet about Medco's margins.
The Motley Fool July 27, 2004 Brian Gorman	Medco's Pumped About Generics Generic drugs are actually helping improve Medco's margins, making it a winner with investors and health-care plans.
The Motley Fool February 23, 2006 Stephen D. Simpson	Express Scripts Overdue for a Pause This pharmacy benefits manager is posting very good growth and has room for improvement, but what about the stock price?
The Motley Fool December 19, 2006 Matthew Crews	Express Scripts' Takeover Battle The pharmacy benefits manager challenges CVS with a higher bid for rival Caremark RX. Investors, stay tuned -- this is far from over.
The Motley Fool June 2, 2011 Dee Gill	CVS's Improved Performance Begins to Drown Out the Dump-Caremark Chants Is the prognosis for CVS looking up?
The Motley Fool June 10, 2010 Claire Stephanic	CVS Caremark vs. Walgreen The two go head-to-head in competition for pharmacy customers.
Managed Care October 2003	Medco Health Solutions tops consumer survey The 2003 WilsonRx Survey reports that patients have identified Medco Health Solutions as the top pharmacy benefit manager for the third year in a row.
The Motley Fool May 8, 2007 Ryan Fuhrmann	CVS/Caremark Tie the Knot While it's too early to see if CVS blazed a new health-care trail by combining a drugstore chain with giant pharmacy benefit manager Caremark, there are still interesting tidbits to pass along to investors from recently reported results.
The Motley Fool July 30, 2009 Brian Orelli	A Good Business Model for Bad Times Some businesses benefit when people are hurting. It's a beautiful time to be a pharmacy benefit manager, since that business model essentially results in them making more money when their customers save money.
The Motley Fool August 1, 2007 Ryan Fuhrmann	Foolish Forecast: CVS Caremark Gets Ready to Rumble CVS Caremark will announce its first combined quarterly results tomorrow. Competitors will be watching to see if the merger of drugstore chain and pharmacy benefit manager is a healthy one.
Managed Care November 2005	Recently Introduced Generics Helped Pbm Control Its Costs The top five generic drugs released over the past three years reduced pharmacy spending by 4.8 percent largely due to the timing of the release of generic products to the market.
The Motley Fool November 2, 2006 Ryan Fuhrmann	CVS Blazes a New Healthcare Trail Strong third-quarter earnings aside, the merger announcement with pharmacy benefit manager Caremark was the real shocker here. Investors, take note.
The Motley Fool February 14, 2005 Brian Gorman	GM Pulls Out of Walgreen The pharmacy's mail-order policy spurs the automaker's cost-containment decision.
The Motley Fool April 27, 2005 Brian Gorman	Cautious on Medco Medco's earnings were respectable, but for now investors may want to step back.
The Motley Fool August 3, 2007 Ryan Fuhrmann	CVS Caremark Is No Sicko Pharmacy powerhouse CVS Caremark is looking to blaze a new health-care trail with the recent merger of their drugstore and pharmacy benefit management operations.
The Motley Fool October 28, 2010	Our Top Stock Idea Our investing community's latest prime pick -- Medco Health Solutions.
The Motley Fool August 31, 2011 Shubh Datta	CVS Caremark Flattened by Higher Costs CVS Caremark profits remained relatively flat this quarter despite a substantial increase in revenue.
The Motley Fool July 18, 2008 Rich Duprey	More Group Therapy From Generics The Teva deal for Barr shows consolidation is still underway in the industry.
The Motley Fool March 6, 2009 Brian Orelli	Don't Let It Go! Health insurer WellPoint is trying to sell its pharmacy business management segment. Is it the right move for them for right now?
Managed Care January 2007 Martin Sipkoff	Employers Want Plans & PBMs To Push Hard for Generics Health insurers' aggressive stand on members' use of generic drugs can attract new clients, but does it interfere with the physician-patient relationship?
The Motley Fool July 29, 2004 Brian Gorman	Express Scripts' Bad Day Express Scripts joins other pharmacy benefit managers (PBM) embroiled in legal controversy. But the company, and its competitors, will eventually emerge from the fray and their stocks may then be worth another look.
The Motley Fool October 2, 2011 Shubh Datta	Would You Invest in This Drug Retailer? Is CVS Caremark worth your investment?
The Motley Fool July 25, 2005 Stephen D. Simpson	Teva Tries to Buy Back the Top Spot $7.4 billion later, Teva Pharmaceuticals is poised to become the largest generics company in the world once again. Investors, take note.
The Motley Fool October 27, 2005 Stephen D. Simpson	Can ESRX Spell P-r-o-f-i-t-s? A company focused on lowering medical costs sounds like a good idea, but investors should dig deeper. While pharmaceutical benefits manager Express Scripts offers high growth and high valuation, it may also offer higher-than-average risk.
Managed Care September 2006 Martin Sipkoff	Specialty Pharmacy Grows As Cost-Control Option As the population ages, specialty pharmacy is becoming a unique, profitable, and invaluable delivery system. Plans are increasingly turning to specialty pharmacies to provide the expertise they lack.
The Motley Fool October 24, 2006 Brian Gorman	Medco's Fringe Benefits Recent developments will present some challenges, but Medco remains a solid long-term investment.
The Motley Fool April 19, 2011 Bryan White	Rising Star Buy: Medco Health Medco has a much brighter future than its current stock price implies.
Managed Care December 2006	The Formulary Files Four core strategies are used to manage outpatient specialty pharmacy costs.
The Motley Fool May 4, 2011 Jason Knapp	Generic Drugs and Old People Could Make You Rich CVS hasn't generated market-beating returns yet -- but it will.
Managed Care September 2005 Martin Sipkoff	Mail Order Pharmacy Saves Money, Says PCMA, but at What Cost? The savings to consumers and employers are apparent, but are health plans left holding the bag in mail-order pharmacy?
The Motley Fool February 15, 2005 Stephen D. Simpson	Teva: Scourge of the Drug World? The world's largest generics maker continues to post strong growth by bedeviling Big Pharma.
The Motley Fool July 6, 2007 Mike Cianciolo	Walgreen: The New Deal Maker Walgreen announces its latest acquisition as it tries to keep pace with the competition. Investors, take note.
Pharmaceutical Executive October 1, 2011	30 Years of Pharma: Perspective in Numbers, Part 3 Top 10 generics companies.
The Motley Fool August 1, 2008 Brian Orelli	Express Scripts Gets More Generic Pharmacy benefits manager Express Scripts may not have grown the top line by much in the second quarter, but using more generic drugs had a positive effect on the bottom line.
The Motley Fool December 6, 2007 Selena Maranjian	Your Drugs Are in the Mail Order medications online and save. According to a study by the Lewin Group, mail-order pharmacies, such as Medco and Express Scripts, can save you as much as 10% overall.
The Motley Fool May 16, 2007 Rich Duprey	Mylan's Costly Bid to Capture the Flag Its winning bid for a German Merck unit might be why it's falling behind in the generics game. Investors, take note.
The Motley Fool April 13, 2009 Brian Orelli	Prescriptions for Acquisitions Express Scripts announces that it is buying WellPoint's NextRx pharmaceutical benefit management subsidiaries for almost $4.7 billion.
The Motley Fool October 5, 2011 Dan Caplinger	Has Teva Pharmaceutical Become the Perfect Stock? Teva still looks poised to stay near perfection for the indefinite future.
Managed Care November 1999	Headlines On Deadline... MedPartners Inc. renamed to Caremark Rx Inc.... Tufts Health Plan will boost premiums... The Pacific Business Group on Health named Blue Cross of California its 2000 Blue Ribbon health plan...
The Motley Fool November 3, 2010 Brian Orelli	A Generic Prescription for Double-Digit Growth MedcoHealth Solutions has it.
The Motley Fool November 4, 2009 Brian Orelli	This One Is Thriving in a Recession Saving customers money makes it easy for Medco.
The Motley Fool June 30, 2005 Brian Gorman	The Co-Pay Effect Higher co-payments look like the wave of the future, and investors should expect the trend to boost major generic players like Teva Pharmaceutical, Mylan Laboratories, and Novartis.
The Motley Fool August 1, 2005 Stephen D. Simpson	Teva: Built to Last? Israeli generics giant Teva Pharmaceuticals is a high-quality company trading at a level that should still provide patient investors with solid long-term performance.
The Motley Fool June 12, 2006 Brian Gorman	Biogeneric Payoff? A new report indicates that spending on specialty drugs increased 17.5% in 2005. This growth bodes well for makers of biotech drugs, which make up a large portion of the specialty drug category. Investors, take note.
The Motley Fool May 10, 2006 Stephen D. Simpson	Time to Make Room for Teva? This might be a rare chance to pick up a dominant company at an attractive price. Investors, take note.